AzTrials
AzTrials

PregnancyPhase 2NCT01766089

Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery

A Phase 2 study testing Remifentanil and Dexmedetomidine in people with Pregnancy and Severe Pre-eclampsia, run by Mansoura University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Preeclampsia is a pregnancy-specific, multisystem disorder that complicates approximately 5 % of pregnancies. Tracheal intubation in the women with severe pre-eclampsia is usually associated with exaggerated transient increases in blood pressure, heart rate and maternal plasma catecholamine concentrations. Read more about this study

Who is it for?
Ages 18 to 40 years, women only
Conditions the study is for
Pregnancy, Severe Pre-eclampsia
What is being tested?
Remifentanil and Dexmedetomidine
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteEgypt
Study dates
Jan 2013to Jan 2017
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • gestational age ≥ 34 weeks
  • severe pre-eclampsia
  • symptoms of imminent eclampsia
  • Caesarean delivery
  • General anaesthesia

Who cannot join

  • allergy to dexmedetomidine
  • cardiac disease
  • pulmonary disease
  • hepatic disease
  • renal disease
  • neurological disease
Show all 23Show fewer
  • neuromuscular disease
  • body mass index >35kg/m2
  • diabetes mellitus
  • anemia
  • coagulation disorders
  • bleeding disorders
  • seizures
  • Hemolysis, Elevated Liver enzymes and Low platelet count (HELLP) syndrome
  • receiving cardiovascular medications
  • receiving antipsychotic medications
  • receiving hypnotic medications
  • alcoholic
  • drug abuse
  • foetal distress
  • placenta praevia
  • abruptio placenta
  • multiple pregnancy

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Mansoura University Hospitals

    Al Mansurah, DK, 050

Other trials in Egypt

About this study

Official title: Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery

Preeclampsia is a pregnancy-specific, multisystem disorder that complicates approximately 5 % of pregnancies.

Tracheal intubation in the women with severe pre-eclampsia is usually associated with exaggerated transient increases in blood pressure, heart rate and maternal plasma catecholamine concentrations. These changes may lead to maternal cerebral oedema, haemorrhage, left ventricular failure, pulmonary oedema or mortality, and reduce uterine blood flow which may adversely affect the neonatal wellbeing. Therefore, the attenuation of the haemodynamic responses to tracheal intubation in this unique group of patients is demanding for the best of both mother and foetus.

Read more

The use of single remifentanil boluses of 0.5 to 1 µg/kg reduces effectively the haemodynamic and catecholamine responses to laryngoscopy and tracheal intubation in severe pre-eclamptics during Cesarean delivery under general anesthesia. Unfortunately, the use of 1 µg/kg doses are associated with more maternal hypotension and neonatal respiratory depression requiring resuscitation. Moreover, the use of preinduction remifentanil bolus of 0.5 µg/kg followed by a continuous infusion at 0.15-0.2 µg/kg/min is associated with significant attenuation of the maternal stress response to tracheal intubation with variable degree of neonatal depression in non-pre-eclamptic women. Whereas, the use of infusion rates of 0.1 µg/kg/min or less is less likely to produce neonatal depression.

In our previous study, we demonstrated that the preoperative administration of dexmedetomidine 0.4 and 0.6 µg/kg/h, a specific alpha 2-adrenoceptor agonist, blunts the maternal haemodynamic and hormonal responses to Caesarean delivery under sevoflurane anaesthesia without adverse neonatal effects. However the use of 0.6 µg/kg/h doses is associated with higher postoperative sedation scores.

Read the detailed description

We hypothesize that the preoperative intravenous dexmedetomidine (0.4 µg/kg/h) and remifentanil (0.1 µg/kg/min) infusions will have comparable maternal haemodynamic responses to tracheal intubation, surgical stimulation and extubation after uncomplicated Caesarean delivery under general anesthesia in parturients with severe pre-eclampsia, without adverse neonatal effects.

Anaesthetic management will be standardized in all studied patients. Oral ranitidine 150 mg and metoclopramide 10 mg will be given the night before and on the morning of surgery, with 0.3 mol/L sodium citrate 30 mL given 15 min before induction. Magnesium sulphate will be given as a loading dose of 4 g intravenously, followed by i.v. infusion of 1g/hour for seizures prophylaxis.

Intravenous boluses of hydralazine 5 mg at 20-min intervals will be used if SAP increases above 160 mm Hg or DAP above 110 mm Hg, to keep the diastolic blood pressure at approximately 90 mmHg and the doses used will be recorded.

The studied population will be allocated randomly to one of two groups, (n = 18, in each), by drawing sequentially numbered sealed opaque envelopes containing a software-generated randomization code (Random Allocation Software, version 1.0.0, Isfahan University of Medical Sciences, Isfahan, Iran), to receive either dexmedetomidine (0.4 µg/kg/h) or remifentanil (0.1 µg/kg/min) starting 20 and 5 min before induction of anaesthesia, respectively, and will be discontinued after peritoneal closure. The dexmedetomidine and remifentanil solutions looked identical.

One anaesthesiologist who is not otherwise involved in the study, will prepare the study solutions, install them in the infusion pumps, set up the dose according to the assigned randomized dose, and will mask the infusion pumps with an opaque sheet throughout the procedure to ensure the blindness of the assessors. Another anaesthesiologist who will be blinded to treatment regimen provided perioperative care. A third anaesthesiologist will collect perioperative data. All staff in the operating room will be unaware of patient allocation.

Maternal monitoring will include three lead-electrocardiography, non-invasive blood pressure, and pulse oximetry. Left uterine displacement will be maintained.

After preoxygenation for 3 min, rapid sequence induction will be performed using propofol 1.5-2.5 mg/kg and suxamethonium 1 mg/kg with the application of cricoid pressure from the time of loss of the consciousness until the inflation of the cuff of the endotracheal tube. Laryngoscopy will be performed after the 1-min blood pressure recording, and tracheal intubation will be completed before the 2-min reading. Correct placement of the endotracheal tube will be confirmed with direct visualization of the passage of its tip between the vocal cords, auscultation of equal breath sounds on both sides of the chest and capnography waveform. The patient's lungs will be mechanically ventilated to maintain (ETCO2) at 30-35mmHg. Anaesthesia will be maintained with a 0.5-0.7% minimum alveolar concentration of sevoflurane in oxygen. Atracurium 0.5 mg/kg will be given for muscle relaxation to maintain suppression of the second twitch using a train-of-four stimulation. The Induction-to-delivery time will be recorded using a stopwatch.

After the umbilical cord is clamped, a 5-10 IU infusion of oxytocin in 500 mL of lactated Ringer's solution will be started and morphine 0.1 mg/kg will be given. After peritoneal closure, study solution will be discontinued.At the end of surgery, sevoflurane will be discontinued, residual neuromuscular block will be antagonized and the trachea will be extubated.

Postoperative analgesia will be achieved according to the authors' hospital protocol with 12-hourly IM diclofenac (75 mg), 6-hourly IVI paracetamol (1 g), and rescue doses of IV meperidine (25 mg).

Statistical analysis:

Data will be tested for normality using the Kolmogorov-Smirnov test. X2 test will be used for categorical data. Repeated-measures analysis of variance will be done to test the serial changes in hemodynamic and cortisol data. Student-t- and Mann Whitney U tests will be used to compare the parametric and nonparametric data between the two studied groups. Data will be expressed as mean (SD), number (%), or median [range]. p < 0.05 will be considered to represent statistical significance.

In a previous study, Yoo et al have demonstrated that the mean (SD) values of MAP at 1 min after tracheal intubation in those received remifentanil bolus were 118 (20) mm Hg. A priori power analysis revealed that 16 patients would be needed in each group to detect a 20% difference in MAP values, 1 min after intubation, after the administration of remifentanil with a type I error of 0.05 and a power of 90%. We assumed that the detection of 20% differences in the mean MAP would be of clinically importance. We increased the sample size by 10% to compensate for patients dropping out during the study.

Keywords
Caesarean delivery, severe pre-eclampsia, remifentanil, dexmedetomidine, cardiovascular response
Medical subject headings
Pre-Eclampsia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RemifentanilDrug

    Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.

  • DexmedetomidineDrug

    dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure

Study groups in NCT01766089
Study groupRoleWhat they receive
DexmedetomidineActive comparatordexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
Receives: Drug: Dexmedetomidine
RemifentanilPlacebo comparatorremifentanil intravenous infusion rate of 0.1 µg/kg/min
Receives: Drug: Remifentanil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean blood pressure

    Mean blood pressure

    Measured: Changes from baseline for 60 min after delivery

Secondary outcomes (6)
  1. Systolic blood pressure

    Systolic blood pressure

    Measured: Changes from baseline for 60 min after delivery

  2. Heart rate

    Heart rate

    Measured: Changes from baseline for 60 min after delivery

  3. Diastolic blood pressure

    Diastolic blood pressure

    Measured: Changes from baseline for 60 min after delivery

  4. neonatal Apgar scores

    Apgar scores

    Measured: from delivery to 5 minutes after that

  5. Neurologic and adaptive capacity score

    Neonatal neurologic and adaptive capacity score (NACS)

    Measured: for 24 hours after delivery

  6. Maternal Cortisol

    Plasma cortisol level

    Measured: from baseline for 1 hour after delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2013 (estimated)
  2. Study startJan 2013
  3. Primary completionDec 2016
  4. Study completionJan 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01766089
Sponsor's protocol ID
R/61
Other IDs
R/61
Status last verified
Jan 2017
First submitted
7 Jan 2013
Last updated
23 Jan 2017
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Remifentanil and Dexmedetomidine in people with Pregnancy and Severe Pre-eclampsia, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean blood pressure (time frame: Changes from baseline for 60 min after delivery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in